Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Gruben

Showing results (21-30 of 68) with videos related to

Pageof 7
Sort By:
Current Medical Research and Opinion|July 7, 2018
Modelling the cost-effectiveness of tofacitinib for the treatment of rheumatoid arthritis in the United StatesLindsay Claxton, Matthew Taylor, Robert A Gerber, et al.
Rheumatology (Oxford, England)|August 15, 2019
Experience with tofacitinib in Canada: patient characteristics and treatment patterns in rheumatoid arthritis over 3 yearsJanet Pope, Louis Bessette, Niall Jones, et al.
Clinical Therapeutics|June 6, 2022
Impact of Methotrexate Discontinuation, Interruption, or Persistence in US Patients with Rheumatoid Arthritis Initiating Tofacitinib + Oral Methotrexate CombinationStanley B Cohen, Boulos Haraoui, Jeffrey R Curtis, et al.
Arthritis Research & Therapy|November 5, 2015
Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDsVibeke Strand, Joel Kremer, Gene Wallenstein, et al.
Digestive Diseases (Basel, Switzerland)|December 8, 2021
Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative ColitisMillie D Long, Russell D Cohen, Timothy W Smith, et al.
Rheumatology and Therapy|April 13, 2026
Effectiveness and Safety of Tofacitinib Up to 36 Months in Canadian Patients with Rheumatoid Arthritis: Final Results from the CANTORAL StudyBoulos Haraoui, Denis Choquette, Cristina Sciortino, et al.
Rheumatology and Therapy|November 11, 2019
Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid ArthritisGeorge W Reed, Robert A Gerber, Ying Shan, et al.
Arthritis Research & Therapy|September 25, 2016
Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trialsRobert B M Landewé, Carol A Connell, John D Bradley, et al.
BMJ Open|December 25, 2025
Sex differences in the efficacy, safety and persistence of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of phase III and long-term extension trialsVibeke Strand, Hendrik Schulze-Koops, Samar Al-Emadi, et al.
Arthritis Care & Research|September 5, 2014
Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trialVibeke Strand, Gerd R Burmester, Cristiano A F Zerbini, et al.
Pageof 7

Showing results (21-30 of 68) with videos related to

Sort By:
Pageof 7
Current Medical Research and Opinion|July 7, 2018
Modelling the cost-effectiveness of tofacitinib for the treatment of rheumatoid arthritis in the United StatesLindsay Claxton, Matthew Taylor, Robert A Gerber, et al.
Rheumatology (Oxford, England)|August 15, 2019
Experience with tofacitinib in Canada: patient characteristics and treatment patterns in rheumatoid arthritis over 3 yearsJanet Pope, Louis Bessette, Niall Jones, et al.
Clinical Therapeutics|June 6, 2022
Impact of Methotrexate Discontinuation, Interruption, or Persistence in US Patients with Rheumatoid Arthritis Initiating Tofacitinib + Oral Methotrexate CombinationStanley B Cohen, Boulos Haraoui, Jeffrey R Curtis, et al.
Arthritis Research & Therapy|November 5, 2015
Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDsVibeke Strand, Joel Kremer, Gene Wallenstein, et al.
Digestive Diseases (Basel, Switzerland)|December 8, 2021
Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative ColitisMillie D Long, Russell D Cohen, Timothy W Smith, et al.
Rheumatology and Therapy|April 13, 2026
Effectiveness and Safety of Tofacitinib Up to 36 Months in Canadian Patients with Rheumatoid Arthritis: Final Results from the CANTORAL StudyBoulos Haraoui, Denis Choquette, Cristina Sciortino, et al.
Rheumatology and Therapy|November 11, 2019
Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid ArthritisGeorge W Reed, Robert A Gerber, Ying Shan, et al.
Arthritis Research & Therapy|September 25, 2016
Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trialsRobert B M Landewé, Carol A Connell, John D Bradley, et al.
BMJ Open|December 25, 2025
Sex differences in the efficacy, safety and persistence of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of phase III and long-term extension trialsVibeke Strand, Hendrik Schulze-Koops, Samar Al-Emadi, et al.
Arthritis Care & Research|September 5, 2014
Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trialVibeke Strand, Gerd R Burmester, Cristiano A F Zerbini, et al.
Pageof 7